Drugs / ATG
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02722668 | May 2017 → Feb 2023 | Burkitt lymphoma, Hodgkins lymphoma, T-cell and NK-cell neoplasm, T-cell non-Hodgkin lymphoma +12 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02722668 ↗ |
| Route | Intravenous | “15 mg/kg IV every 12 hours Day -6 to Day -4” NCT02722668 ↗ |